Article
Become a Member to Save

LIVTENCITY▼® (maribavir) safety data

LIVTENCITY (maribavir) is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).1
Consideration should be given to official guidance on the appropriate use of antiviral agents.1

In the pivotal Phase 3 trial, LIVTENCITY delivered double the viraemia clearance (55.7%) compared to investigator-assigned therapy (IAT) (23.9%) – primary endpoint2

Confirmed viraemia clearance* of refractory CMV in all transplants (HSCT and SOT) at Study Week 82

*Plasma CMV DNA <137 IU/mL in 2 consecutive tests ≥5 days apart.2

LIVTENCITY (maribavir) — positive safety profile in post-transplant refractory CMV (with or without resistance)

LIVTENCITY treatment-related adverse events compared to IAT2,3

In the SOLSTICE trial, the most reported treatment-related adverse event was dysgeusia (35.9% [84/234] vs 0.9% [1/116] receiving IAT) that typically resolved during or after treatment.3